US Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (Nivolumab and Relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma

By
Justin.choi
-
0
60
Bristol Myers Squibb announced that OpdualagTM was approved by the FDA for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.
[Bristol Myers Squibb]

Sorry, but the selected Zotpress account can't be found.

Press Release